Tissue-Based Genomic Testing in Prostate Cancer: 10-Year Analysis of National Trends on the Use of Prolaris, Decipher, ProMark, and Oncotype DX.
Eugenio BolognaFrancesco DitonnoLeslie Claire LicariAntonio FrancoCeleste ManfrediSpencer MossackSavio Domenico PandolfoCosimo De NunzioGiuseppe SimoneCostantino LeonardoGiorgio FrancoPublished in: Clinics and practice (2024)
Our analysis indicates a growing trend in the utilization of tissue-based genomic testing for PCa. Nevertheless, they are utilized in less than 2% of PCa patients, whether at initial diagnosis or after surgical treatment. Although it is anticipated that their use may increase as more scientific evidence becomes available, their role requires further elucidation.